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In large cohort studies comorbidities are usually self-reported by the patients. This way to
collect health information only represents conditions known, memorized and openly
reported by the patients. Several studies addressed the relationship between self-reported
comorbidities and medical records or pharmacy data, but none of them provided a struc-
tured, documented method of evaluation. We thus developed a detailed procedure to com-
pare self-reported comorbidities with information on comorbidities derived from medication
inspection. This was applied to the data of the German COPD cohort COSYCONET.
Methods
Approach I was based solely on ICD10-Codes for the diseases and the indications of medi-
cations. To overcome the limitations due to potential non-specificity of medications,
Approach II was developed using more detailed information, such as ATC-Codes specific
for one disease. The relationship between reported comorbidities and medication was
expressed by a four-level concordance score.
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Results
Approaches I and II demonstrated that the patterns of concordance scores markedly dif-
fered between comorbidities in the COSYCONET data. On average, Approach I resulted in
more than 50% concordance of all reported diseases to at least one medication. The more
specific Approach II showed larger differences in the matching with medications, due to
large differences in the disease-specificity of drugs. The highest concordance was
achieved for diabetes and three combined cardiovascular disorders, while it was substan-
tial for dyslipidemia and hyperuricemia, and low for asthma.
Conclusion
Both approaches represent feasible strategies to confirm self-reported diagnoses via medi-
cation. Approach I covers a broad spectrum of diseases and medications but is limited
regarding disease-specificity. Approach II uses the information from medications specific
for a single disease and therefore can reach higher concordance scores. The strategies
described in a detailed and reproducible manner are generally applicable in large studies
and might be useful to extract as much information as possible from the available data.
Introduction
Comorbidities in chronic conditions such as Chronic ObstructivePulmonaryDiseases (COPD)
are known to influence prognosis, health status and therapy options [1]. For large cohorts the
assessment of comorbidities is challenging and different tools are used to obtain and evaluate
information on coexisting diseases (e.g. Charlson-Comorbidity-Index [2], ATS-DLD-78 [3]).
Self-reporting of diagnoses is a common approach to collect data on health status [4]. Much
work has been invested to assess the value of self-reported data in comparison to other sources
of information like pharmacy records on medications, or medical records from general practi-
tioners (GP), nurses etc. [5–8]. Information on comorbidities given by the patients has been
described to be reliable [9–11] especially for chronic conditions such as diabetes or heart dis-
ease [12]. Despite this, depending on the disease and several influencing factors it was found
that in some cases patients’ reports tend to underestimate relevant comorbidities [5–7] but
overestimation could also be demonstrated [12]. Therefore it has been recommended to take
into account all available sources of information in the assessment of comorbidities [7, 13].
To identify and predict frailty in the elderly, Coelho et al. not only collected health data
from self-reports but also evaluated specificmedications [14]. Medication was categorized into
groups of indications (e.g. cardiovascular, metabolic), however the categories were rather
broad and no detailed description was given how to categorize and match the medications. The
need for a combined evaluation of comorbidities and medication is also evident in the German
COPD cohort COSYCONET which comprises more than 2500 patients [15–17]. In order to
use as much information as possible we developed a novel categorization in which the concor-
dance betweenmedication and patients’ reports on comorbidities is evaluated. This approach
which is described in all necessary detail might also be useful for other large cohort studies on
respiratory or other diseases probing the influence of comorbidities on outcome and prognosis.
Methods
COSYCONET is a multicenter cohort study focusing on disease progression over time in inter-
action with comorbidities [15]. All assessments were approved by the central (Marburg
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(Ethikkommission FB Medizin Marburg) and local ethical committees (see S1 Ethics Commit-
tees) and written informed consent was obtained from all patients. The study was in accor-
dance with the declaration of Helsinki. The present analysis is based on data from the
recruitment visit comprising COPD-patients of categories GOLD 0-IV [18] (n = 2653; for
basic characteristics see Table 1). Data collectionwas performed from September 2010 to
December 2013. All patients were required to be diagnosedwith COPD or chronic bronchitis
and an age of at least 40 years was required. Only few exclusion criteria were defined (e.g. lung
surgery with great volume reduction, exacerbations within 4 weeks prior to baseline visit) since
the study aimed at capturing a broad spectrumof patients with COPD. Comorbidities were
assessed using a predefined list comprising a total of 51 (combined) diseases, as well as free text
information. Moreover, patients were asked to bring all medication (original packages) to their
study visit. Patients’ previous medical records were not evaluated due to issues of data quality
and completeness. We solely used self-reports of physician-diagnosed conditions for morbidi-
ties, with medication brought to the visit being the supplementary source to be compared with
diagnoses. Two approaches (I and II, see description below) were developed for a quality com-
parison. Approach II aimed at overcoming some of the limitations inherent to Approach I.
Approach I for comparison of self-reported diagnoses
The first step was to transform comorbidities and medications into codes which could be
matched by computer analysis. “Non-insulin dependent diabetes mellitus” and “insulin-depen-
dent diabetes mellitus” were combined into “diabetes mellitus”, and reflux, gastritis and gastric
and duodenal ulcerations into “gastro-intestinal disorders” (GI). In addition to the individual
analyses, hypertension, coronary heart disease and heart failure were merged into a disease entity
“combined cardiovascular disorder” to take account of the fact that there was a lack of medica-
tion specific for the single diseases, but specificmedication for their combination is available.
“Mental disorders” comprised depression, anxiety, panic attacks and psychotic disorders.
ICD10-Codes for comorbidities. To classify the reported diagnoses the system of Interna-
tional Classification of Diseases, version 10 (ICD10 [19]) was employed. ICD10-Codes com-
prise up to 5 digits (structure: X00.00). From the patients’ reports only limited information was
available necessitating the definition of lumped categories. Thus, comorbidities were coded by
ICD10-Codes but in most cases without applying subcategories. Except for sleep apnea, dis-
turbed blood flow in the legs, and vein thrombosis we used only the first three digits.
In some instances a combination of three-digit codes was required since the single codes
were not sufficient to describe the comorbidities. This applied e.g. for the integrative category
of “coronary heart disease” which comprised I20: Angina pectoris, I24: Other acute ischemic
heart diseases, and I25: Chronic ischemic heart disease. Table 2 shows all comorbidities men-
tioned by more than 400 patients or considered relevant in COPD. The full table of categories
can be found in the S1 Table.
Table 1. Basic characteristics of the patients stratified according to COPD GOLD categories 0–4.
Patients (n) Age Mean (±SD) BMI Mean (±SD) # of self-reported comorbidities Mean (±SD) Male Total number (%)
All (2653) 65.0 (±8.6) 27.0 (±5.4) 6.0 (±3.4) 1575 (59.4)
GOLD 0 (362) 64.8 (± 9.7) 29.0 (± 5.8) 7.1 (± 3.7) 179 (49.4)
GOLD 1 (206) 66.2 (± 8.7) 26.6 (± 4.6) 6.2 (± 3.3) 124 (60.2)
GOLD 2 (962) 65.7 (± 8.5) 27.4 (± 5.1) 5.9 (± 3.3) 579 (60.2)
GOLD 3 (874) 65.0 (± 8.2) 26.4 (± 5.4) 5.8 (± 3.3) 533 (61.0)
GOLD 4 (249) 62.1 (± 7.9) 24.4 (± 5.0) 5.1 (± 3.0) 160 (64.3)
doi:10.1371/journal.pone.0163408.t001
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Transformation of ICD10-Codesof medication for the purpose of matching. Indica-
tions for each reported drug were retrieved from the AiDKlinik software program [20] using
the PZN (pharmacological registration number in Germany) if available, or alternatively
names, dosages and companies. In the next step a special dictionarywas created to translate
and re-code from the detailed 5-digit ICD10-Codes of the medication into single or multiple
3-digit-codes. This enabled the matching with the comorbidity codes. Table 3 illustrates the re-
coding algorithm for selected comorbidities (for the full dictionary see S2 Table). Each code
occurred only once for each patient even if more than one drug with the same indication had
been prescribed. The conversion from detailed ICD10-Codes into the comprehensive, merged
codes and their matching with comorbidity ICD10-Codeswas performed in the programming
language R 3.2.2 [21].
Table 2. ICD10 coding of relevant and/or prevalent comorbidities as used in the analysis of
Approach I.
Disease (% prevalence self-
reports)
Associated ICD10-Codes
Hypertension (56.1%) any codes from I10 to I15
Dyslipidemia (39.0%) E78
Gastrointestinal (36.5%) any codes from K20 to K31 or R12
Mental disorders (21.4%) F00 or any codes from F07 to F09 or any codes from F20 to F49 or
any codes from F51 to F99
Asthma (18.5%) J45 or J46
Hyperuricemia (16.6%) E79 or M10
Coronary heart disease (16.1%) I20 or I24 or I25
Osteoporosis (15.2%) any codes from M80 to M85
Diabetes mellitus (13.6%) any codes from E10 to E14
Combined cardiovascular disorder
(60.8%)
any codes from I10 to I15; I20 or I24 or I25; I50
doi:10.1371/journal.pone.0163408.t002
Table 3. List of ICD10-Codes used for comparison of comorbidities and medication.
Disease Disease ICD10-Code Leading three digits of medication ICD10-Codes
Hypertension I10-I15 - any code from I10.XX to I15.XX
Dyslipidemia E78 - E78.XX
Gastrointestinal (GI) K20-K31; R12 - any code from K20.XX to K31.XX
- R12.XX
Mental disorders F00; F07-F09;F20-F49; F51-F99 - F00.XX
- F07.XX or F08.XX or F09.XX
- any code from F20.XX to F49.XX
- any code from F51.XX to F99.XX
Asthma J45-J46 - J45.XX or J46.XX
Hyperuricemia E79; M10 - E79.XX
- M10.XX
Coronary heart disease I20; I24; I25 - I20.XX or I24.XX or I25.XX
Osteoporosis M80-M85 - any code from M80.XX to M85.XX
Diabetes mellitus E10-E14 - any code from E10.XX to E14.XX
Combined cardiovascular disorder I10-I15; I20, I24, I25; I50 - any code from I10.XX to I15.XX
- I20.XX or I24.XX or I25.XX
- I50.XX
The second column of the table shows the ICD10-Codes of the diseases listed in the first column. The third column shows the merged ICD10-Codes of
medication that were assigned to the ICD10-Codes of column 2. As illustrated in column 3, for the assignment the leading three digits of the medication
ICD10-Codes were used.
doi:10.1371/journal.pone.0163408.t003
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Matching of ICD10-Codesbetween comorbidities and medication. The comparison led
to three different classes. Either the intake of a medication was concordant with the reported
disease (class 1), or a disease was reported without a matching medication (class 2). The possi-
bility that there was a medication without a corresponding disease in the patient’s report was
not evaluated as medications were not necessarily specific for a disease. The natural limitation
of this approach results from the fact that medications were classified according to their indica-
tion in a given comorbidity but without requiring that this comorbidity was the only indication
for this medication.
Approach II for comparison of self-reported diagnoses
The basic idea of Approach II was to identify drugs having only one indication (according to
the ICD10-Code indication list of the AiDKlinik database) and to use only these drugs to verify
a reported disease. Such drugs could also serve as indicators of a disease if the comorbidity was
not reported by the patient. This approach seemed reasonable especially for chronic conditions
requiring sustained treatment.
Identification of medications specific for a disease. The 9 diseases and one disease com-
bination chosen for analysis were hypertension, dyslipidemia, GI, mental disorders, asthma,
coronary heart disease, hyperuricemia, osteoporosis, diabetes mellitus, as well as combined car-
diovascular disorder. This combination was chosen not from a clinical but a pharmaceutical
perspective, since many frequently prescribedmedications (beta blockers, ACE inhibitors, AT1
receptor antagonists) are indicators of at least one of the conditions included in the combined
cardiovascular disorder. In a first step the AiDKlinik database was searched for specific ATC-
Codes indicating exclusively one disease (disease complex).
In the second step two qualified researchers (TL pharmacist, HM chemist and physician
with focus on pharmacology) verified the specificity of medications. All drugs reported in
COSYCONET were labeled with the respective ATC-Codes. The tables with all specific codes
needed to categorize diseases can be found in the S3–S12 Tables. In most cases only drugs of
the latest version of the Red List (= Rote Liste; a German registry of marketed drugs, including
EU licenses) were included, with the exception of very few medications which were available at
the time of the visit but out of trade at the time of the evaluation. The information on the drugs
was used to create concordance scores for comorbidities by comparison with their specific
medications.
Definition of concordance scores A and B. The first step was to match ATC-Codes spe-
cific for a disease with the diagnoses reported by the patient. Concordance score A was
assigned if both were in accordance with each other. Patients taking at least one medication
specific for a particular condition but not reporting this disease received score B.
Comparison and Combination of Approaches I and II
The patients which could not be categorized into concordance scores A or B using specific
medications could only be analyzed using the weaker information from Approach I. Approach
II provides a sufficient condition for the presence of the disease, therefore patients can be con-
sidered with high confidence to have the respective comorbidity. In contrast in Approach I
there was only medication compatible with the disease or no medication for the disease at all.
The scores A and B from Approach II were kept in the combined approach. Patients with class
1 from Approach I (intake of a (nonspecific) drug plus report of a corresponding disease) were
labeled as concordance score C, and patients with class 2 (report only) as concordance score D.
The combined approach thus enabled the definition of four concordance scores which were
Analysis of Self-Reported Diseases by Medication
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computed for the comorbidities selected for analysis (see Tables 2 and 4). The matching proce-
dures were again performed by special R-codes.
Results
Table 5 shows the distribution of scores for the 9 analyzed comorbidities and the combined
cardiovascular disorder. The distribution varied between diseases and in particular the contri-
butions of the scores A and D were very different. For selected diseases the pattern is illustrated
in Fig 1 (for all diseases see S1 Fig).
The proportion of patients in whom the comorbidity was in accordance with specificmedi-
cation was highest for diabetes mellitus. Only few patients were identified as taking diabetes-
specificmedication without reported diabetes (2.4% of 371 patients). Similarly, the proportion
of patients with reported diabetes without specific or non-specificmedication was low (16.4%
of 371 patients).
In contrast to diabetes, reported asthma was associated with specificmedication only in a
minority of patients. This was a consequence of the fact that there are very few drugs on the
market which are specific for asthma and not at the same time applicable in COPD. This
reduces the potential to confirm asthma by medication in a cohort in which patients were
required to have COPD. The percentage of patients reporting asthma without any medication
indicating asthma was very low.
Table 4. Overview on the information used for defining the concordance scores.
Concordance score for analyses Self-reported diagnosis Specific medication Non-specific medication
A + +
B - +
C + - +
D + - -
The (+) indicates the information that was used in assigning the concordance scores A-D. The (-) symbolizes the lack of information which therefore could
not be used for the assignment. Please note that the scores C and D were only assigned to patients who were not already categorized in scores A and B.
The empty boxes indicate information that was not considered according to the definition of the concordance scores.
doi:10.1371/journal.pone.0163408.t004
Table 5. Distribution of concordance scores for different comorbidities (percentages based on the total number of included patients (n = 2653)).
Disease Reported Prevalence (n) Prevalence including B (n) Concordance Scores (n)
A B C D
Hypertension 56.1% (1489) 57.4% (1524) 548 35 804 137
Dyslipidemia 39.0% (1035) 43.8% (1163) 499 128 3 533
GI 36.5% (969) 46.4% (1230) 405 261 6 558
Mental disorders 21.4% (567) 24.9% (660) 213 93 28 326
Asthma 18.5% (491) 19.8% (525) 34 34 433 24
Hyperuricemia 16.6% (440) 18.2% (484) 193 44 37 210
Coronary heart disease 16.1% (426) 17.2% (455) 77 29 304 45
Osteoporosis 15.2% (402) 15.7% (417) 108 15 76 218
Diabetes mellitus 13.6% (362) 14.0% (371) 277 9 24 61
Combined CVD 60.8% (1612) 65.6% (1741) 1374 129 75 163
Scores A and B are based on disease-specific medication (ATC-Codes) while score C is assigned based on non-specific medication (ICD10-Codes).
Scores A, C and D require the patient’s report of the respective disease. Only score B is based on specific medication only in the absence of a patient-
reported diagnosis. Therefore scores A and C are directly comparable to each other whereas scores B and D are based on different sources of information.
doi:10.1371/journal.pone.0163408.t005
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An intermediate pattern was observed for hyperuricemia. In a considerable proportion of
patients the self-reported diagnosis was in accordance with the reported intake of specificmed-
ication, and the proportion of non-specificmedication was low. On the other hand 47.7% of
patients reported to have been diagnosedwith hyperuricemia but took neither specific nor
non-specificmedication.
The analysis of coronary heart disease and hypertension showed a very high proportion of
patients in whom the self-reported diagnosis was in accordance to non-specificmedication. In
contrast the percentage identified by specificmedication was low. This reflected the fact that
few drugs are available which are specifically targeted against one of these two diseases. This
becomes apparent in the relatively low number in category A. Only a minority of patients with
coronary heart disease or hypertension could be identified by specific drugs in the absence of a
self-reported diagnosis. In comparison to the single diseases, the level of accordance between
diagnosis and specificmedication was much higher for the combined entity comprising hyper-
tension, coronary heart disease and heart failure. This shows that the combined entity allowed
for a greater number of specificmedications (see S12 Table).
The patterns observed in the other diseases were similar to those of the diseases described
above. Overall, about 51.5% of the reported comorbidities were confirmed by Approach I,
without very large differences between diseases although the number of comorbidities analyzed
Fig 1. Examples of different distribution patterns of the concordance scores for the diseases asthma,
diabetes, hyperuricemia and GI disorders. The values are percentages relative to the total number of patients
(n = 2653). The blue part (A) represents the concordance between reported disease and specific medication, the
red part (C) illustrates self-reports confirmed by non-specific medication. Green parts show the proportion of
patients only reporting a disease without any suitable medication (D). The violet part (B) on top presents patients
without the report of a disease but identified as likely having the disease due to the intake of a specific medication.
The sum of A, C and D represents the prevalence according to self-reports (see Table 5). The distribution patterns
vary widely among the different diseases.
doi:10.1371/journal.pone.0163408.g001
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was much higher than in Approach II. Despite the lower number of comorbidities analyzed, in
Approach II the percentage confirmed by specificmedication (concordance score A) showed
even larger differences between diseases (Table 5 and S1 Fig).
The strategy comprising the combined Approaches I and II was equivalent to the flow chart
shown in Fig 2. The structure of this chart also illustrates why it was possible to add the per-
centages of scores A-D as shown in Fig 1.
Discussion
In COSYCONET, as in many other studies, patients were asked to report physician-diagnosed
comorbidities (“Have you ever been diagnosedwith. . .”). This type of assessment is required
since it is practically impossible to verify a broad spectrumof comorbidities by clinical assess-
ments at the study visits. Obviously, the information depends on the patients’ knowledge,
memory and cooperation. It is also based on the sensitivity and specificity of the assessment of
comorbidities during usual care by the patients’ physicians. Therefore it would be helpful to
increase the reliability of patients’ reports with the help of other data available in the registry.
For this purpose we developed a categorization system comprising four concordance scores for
the reported diseases by using the information on medication. The major outcome was that
about 50% of comorbidities were in accordance with medication when using the non-specific
Fig 2. Diagram showing the logical structure of the combined categorization procedure (Approach I plus
Approach II). A-D indicates the concordance scores,Ø the absence of the disease under study. ATC-Codes refer
to the patients‘ medication, and ICD10 matching to the comparison of medication with the revised ICD10-Codes of
the disease (for details see text).
doi:10.1371/journal.pone.0163408.g002
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Approach I. For a selected number of important comorbidities Approach II showed that the
degree of confirmation differed very much between diseases, particularly diabetes and asthma.
Many studies on multimorbidity have relied on questionnaires asking for self-reported doc-
tor-diagnosed diseases [4, 22]. Studies on the relationship between self-reported and other
medical data [5–7, 9–11] indicated sufficient reliability, especially for highly prevalent chronic
conditions [6–9, 12], however the relationship differed between diseases. Using medical rec-
ords as a gold standard [7, 9, 23] the sensitivities for different diseases turned out to be>0.7
indicating that self-reports can be a valid way to capture comorbidities despite the finding that
for depression/anxiety and peptic ulcer disease sensitivities were lower [23]. These findings
were explained by the fact that patients’ reports depend on disease severity, symptoms, the
characteristics of the comorbidity and the need for ongoing monitoring [10]. Similar results
were shown in a study that did not use a gold standard [12]; the concordance between self-
reports and other sources of information was high for easily memorable, clearly defined condi-
tions such as diabetes or heart disease, while it was lower for depression and lung disorders.
Higher prevalences for self-reports compared to medical records might be due to patients’
recall bias or incomplete records [7, 24] but underreporting is also possible for diseases with
low impact on daily symptoms [6].
In view of these findings the primary aim of our study was to evaluate to which extent infor-
mation derived from medication can be used in different comorbidities; for this purposewe
developed and described in detail a method utilizing these data.
Coelho et al. [14] already addressed the confirmation of self-reports by using medication,
but no detailed information on the method was given. Computerized tools like the RxRisk
Model [25] that have been used to relate ambulatory pharmacy data to chronic conditions can-
not be used in all countries, since the pharmacy management differs and data may not be avail-
able in the proper format. In general, it seems that taking into account several sources of
information for comorbidities leads to the best description of the patients’ comorbidity status
[7, 13]. There is one study in patients with COPD which used medication (diabetes) or bio-
markers (hypertension) to assess the prevalence of clinically relevant comorbidities, but no
details were given on the procedure [26]. Biomarkers pose the problem that they might be
affected by treatment. We therefore developed and describe such a procedure based on medica-
tion. As a further novel contribution concordance scores were defined providing different lev-
els of confidence into the self-reported information on comorbidities.
In Approach I more than half of the reported diseases were found to be compatible with the
intake of medication. This was encouragingwhen considering that some chronic conditions do
not require regular medication and some may only have been present in the past. Nonetheless,
this approach was limited in its confirmatory ability (concordance score C), since it did not
account for the specificity of medication and all possible indications for a drug were admitted,
e.g. in glucocorticoidsmore than 120.
For this reason Approach II was developedwhich allowed the addition of two further con-
cordance scores (A and B). The basic feature was the use of disease-specificmedications. If the
patient’s report and the medication matched, the highest concordance score A was assigned. In
analogy to the RxRisk model score B was defined as probable disease indicated by specificmed-
ication but without reporting of the disease by the patient. Although score B is to be considered
lower than score A, the specificity of medication is strongly suggestive of the comorbidity. The
lowest level of credibility (concordance score D) was given, when neither non-specific nor spe-
cific medication was identified although a patient reported a comorbidity. This is difficult to
interpret since the comorbidity may have been cured or may be mild and does not require
medication. In this case only more specific information, the comparison with the patients’ clin-
ical state and/or biomarkers is capable of giving further clues.
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The identification of specific drugs for GI disorders was difficult since many GI problems
are treated not for chronic but acute conditions. Moreover acute problems of the GI tract are
often caused by other conditions (e.g. diarrhea due to viral infection; vomiting due to use of
cytostatic drugs). Therefore drugs for these types of symptoms were excluded (e.g. loperamide,
metoclopramide). Another problem was that Over-the-counter (OTC) medication is available
for the treatment of chronic GI problems (e.g. omeprazole). A prescribedmedication supports
the assumption that a physician diagnosed the self-reported comorbidity, whereas in case of
OTC medications the self-reported diseasemust not be based on a physician’s diagnosis.More-
over, pantoprazole or omeprazole are often prescribed to prevent GI irritations caused by other
drugs. This reduces the ability to infer a comorbidity from specificmedication in this particular
case.
The differentiation between asthma and other obstructive lung diseases via medication is a
difficult issue. In COSYCONET this posed a particular problem due to the fact that all COSYC-
ONET-patients were required to have a diagnosis of COPD. Many COPD medications are also
prescribed in asthma, such as SABAs, LABAs or inhaled corticosteroids, and there are very few
medications for asthma only. Therefore the opportunity for evaluation of asthma was low. Pos-
sibly a combined diagnosis “obstructive airway disorder” comprising asthma and COPD would
result in a high degree of concordance.
Hypertension was the most often reported comorbidity in COSYCONET. Notably, many
patients with hypertension are not categorized into the highest concordance score A since their
hypertension therapeutics have many further indications. Coronary heart disease is also often
treated by non-specificmedications. We therefore combined coronary heart disease, hyperten-
sion and heart failure into a complex entity and used medication specific for one or more of
these diseases to define concordance scores. This resulted in a high proportion of patients in
concordance score A in comparison to the single diseases. In addition to the pharmaceutical
argument given in the Methods section, we included the analysis of the combined group in
order to illustrate that even with few, clinically heterogeneous diseases a remarkable gain in
concordance score could be achieved, provided that there is medication specific for up to three
of these diseases.
It will depend on the aim of the analyses regarding these comorbidities, whether a high
degree of confirmation for a broader entity or a separation into single diseases is better. Due to
this we cannot give a general recommendation how to use the scores. Self-reports are often
considered sufficient in large epidemiological studies assessing prevalence estimates but score
B may improve the estimates, for diseases on which most medication is specific.
In addition a detailed analysis of medication might be helpful for comparisons between
patients merely reporting the disease versus those adequately treated. Information on specific
medication might also be useful if this medication has pleiotropic effects extending beyond
their specific indication [27, 28]. In contrast, patients with score D could be considered with
caution in the analysis. This applies e.g. to the cardiovascular disorders which commonly
require regular treatment. Overreporting as possibly reflected in score D might be based on
patients’ misinterpretations of medical terminology [29]. We propose that by comparing differ-
ent medication-baseddefinitions of the disease it should be analyzed, whether exclusion of
patients with score D creates more reliable groups. In addition, we expect that such compari-
sons could also be valuable in the analysis of quality of life data which might depend on the
intake of medication in relation to disease severity. In our view, the ICD10-Code-based
approach is useful for the quality check of data in studies relying on self-reports, since at least it
can indicate compatibility betweenmedication and report. These considerations illustrate that
the different approaches and categories developed by us offer several options that can be cho-
sen and adapted according to specific diseases and needs.
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Limitations
The main limitation of this study is the lack of a gold standard to which the data could be com-
pared. Usually medical record abstraction is used as reference, but we could not assess diagno-
ses from the medical records of the patients. This underlines the potential value of a detailed
medication history which might be the only information available in large studies. Even the use
of historical data from prescription files could be useful if potential legal issues can be handled.
Moreover, the distribution of scores varied between diseases, although their definitionwas the
same. This limitation seems to be based in the characteristics of various diseases and difficult to
avoid. A further limitation is that some diseases do not require regular medication or are cur-
able and neverthelessmay have been reported by the patient. There also may be conditions in
which the disorder does not necessarily indicate a disease in the proper sense, but a side-effect
of therapy or other diseases (e.g. GI).
Another reason for insufficient concordance between some diseases and prescribedmedica-
tion might result from the type of questions for comorbidities. The COSYCONET study asked
for any physician-based diagnosis in the patients’ lifetime. Especially for diseases strongly influ-
enced by lifestyle (e.g. changes in nutrition or higher physical activity) or effectively cured (e.g.
depression/anxiety in earlier life time) this can pose a problem which can be overcome by
establishing a more detailed clinical history.
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